AUTHORS
Kartik Lakhotiya, MS, Xiaorong Gu, PhD2, Arda Durmaz, PhD3, Mark David Orland, MD, PhD4, Atsushi Marumo, MD5, Karol K Gostomczyk6, Serhan Unlu, MD7, Felipe de Almeida Sartori8, Charlotte Zurowski9, Carlos Bravo-Perez, MD10, Luca Guarnera, MD11, Nandini Rajaram Siva, MD12, Akram Abushamma, MD13, Jackson Hensley, N/A14, Varun K. Venkatesh, N/A15, Christopher Haddad, BS16, Aashray Mandala, BS17, Ajitesh Reddy Busireddy, N/A18, Vibha Balasubramaniam19, Maxwell Hou, N/A20, Carmelo Gurnari, MD,PhD21, Jaroslaw P. Maciejewski, MD, PhD, FACP22
AFFILIATIONS
1 Case Western Reserve University School of Medicine, Cleveland, Ohio, United States, Cleveland Clinic Foundation, Cleveland, Ohio, United States
2 Cleveland Clinic Foundation, Cleveland, Ohio, United States
3 Cleveland Clinic Foundation, Cleveland, Ohio, United States
4 Case Western Reserve University School of Medicine, Cleveland, Ohio, United States, Cleveland Clinic Foundation, Cleveland, Ohio, United States
5 Cleveland Clinic Foundation, Cleveland, Ohio, United States, Cleveland Clinic Foundation, Cleveland, Ohio, United States, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan
6 Cleveland Clinic Foundation, Cleveland, Ohio, United States
7 Cleveland Clinic Foundation, Cleveland, Ohio, United States
8 Case Western Reserve University School of Medicine, Cleveland, Ohio, United States, Cleveland Clinic Foundation, Cleveland, Ohio, United States, Hospital Israelita Albert Einstein, Sao Paulo, SP, Brazil
9 Cleveland Clinic Foundation, Cleveland, Ohio, United States
10 Hospital Universitario Morales Meseguer, University of Murcia, Murcia, Spain
11 University of Rome Tor Vergata, Roma, Italy
12 Cleveland Clinic Foundation, Cleveland, Ohio, United States
13 Cleveland Clinic Foundation, Cleveland, Ohio, United States
14 Cleveland Clinic Foundation, Cleveland, Ohio, United States
15 Cleveland Clinic Foundation, Cleveland, Ohio, United States
16 Cleveland Clinic Foundation, Cleveland, Ohio, United States
17 Cleveland Clinic Foundation, Cleveland, Ohio, United States
18 Cleveland Clinic Foundation, Cleveland, Ohio, United States
19 Cleveland Clinic Foundation, Cleveland, Ohio, United States
20 Cleveland Clinic Foundation, Cleveland, Ohio, United States
21 Cleveland Clinic Foundation, Cleveland, Ohio, United States, University of Rome Tor Vergata, Roma, Italy
22 Cleveland Clinic Foundation, Cleveland, Ohio, United States
ABSTRACT
The mechanism of immune escape in PNH may involve faulty antigenic peptide presentation. PIGA mutant cells may accumulate uncleaved precursors of GPI anchored proteins that, once processed, could dilute the autoimmune target peptides; alternatively, neopeptides from the C-terminal omega-site junction could act as neoantigens and redirect the immune response. Peptide elution is technically difficult; building on our affinity-column mass spectrometry approach (Blood 2025;146(Suppl 1):3207), we refined it with an HLA-A2 allele-specific column to investigate the HLA-A*02:01 ligandome of PIGA deficient and isogenic wild type TF1 cells.
HLA-A*02:01 complexes were affinity-purified on an anti-A2 antibody column from isogenic TF1 wild type (WT) and PIGA mutant (PIGA) cells, with and without IFN-g (2x2 design, 3 biological and 3 technical replicates each, 36 runs); eluted peptides were analyzed by LC-MS/MS with PEAKS. Unique 8 to 12mers were counted, Tier A requiring at least 2 of 3 biological replicates; binding (NetMHCpan-4.1, MHCflurry) and 9-mer motifs (clustering) were scored.
At baseline, elution of HLA-A2 from the GPI-deficient (PIGA) line yielded 7,209 high confidence (Tier A) peptides and WT 4,929; IFN-g roughly doubled the yield in both lines, to 13,286 and 9,793. Presentation was dominated by 9-mers, and IFN-g both sharpened the anchor (9-mer share 27 to 49% in PIGA, 29 to 53% in WT) and raised their strong-binder fraction (under 500 nM) in both lines, from 35 to 63% in PIGA and 38 to 65% in WT. The two lines overlapped only partly: they shared 3,067 peptides (Jaccard 0.34; 62% of the WT and 43% of the PIGA spectrum), while 4,142 were unique to PIGA (57% of its spectrum) and 1,862 to WT (38%). In balance, PIGA lacked that 38% of the WT peptides yet, through its own additional peptides, presented a 46% larger, more diverse peptidome.
The two lines shared far more of their source proteins than of their peptides (protein Jaccard 0.51 versus 0.34 for peptides at baseline, 0.66 versus 0.44 with IFN-g), so PIGA deficiency changes which fragments of the same proteins are presented.
IFN-g reshaped both peptidomes, more so in PIGA, mainly by adding new peptides (63% of the PIGA and 71% of the WT IFN peptidome was new) and enlarging every compartment: the shared set grew 2.3-fold to 7,099 and PIGA held 2.3 times as many unique peptides as WT (6,187 versus 2,694), from 5,221 versus 4,422 source proteins. The lines converged in what they shared (peptide Jaccard 0.34 to 0.44; r 0.61 to 0.73), and PIGA retained more of its baseline than WT (69 versus 58%).
About half of the peptides shared under IFN-g, roughly 3,600, differed by at least twofold in amount, split almost evenly (about 1,760 higher in PIGA and 1,860 in WT), the largest over a hundredfold. The most PIGA-biased ligands included ALGGVLVGV (SLC9A1), ILADLLPSL (DHRS7B) and NLMEQPIKV (JUP), while WT favoured YLSDFICCL (ABCE1), FLSLINVGL (ANP32B) and ILEDVVGV (TPX2); 11 of 12 were strong A2 binders under 50 nM (median 20 nM), candidate ligands ranked by presentation, not validated neoepitopes. This bias was only weakly reflected at the mRNA level (r 0.34), a largely post-transcriptional change in the peptides presented rather than in gene expression, and about half recurred in a pan-HLA (W6/32) capture.
Among 738 peptides from 177 GPI anchored proteins, the difference localized to the uncleaved signal-anchor region (spanning or downstream of the omega site) that persists only if the GPI anchor is not added. Consistent with accumulation of this uncleaved precursor, PIGA presented significantly more of these peptides than WT: of those seen in only one line, 21 of 27 (78%) were PIGA-specific versus 6 WT-specific, whereas the mature regions showed no such lean (odds ratio 2.7, p 0.037). Two stood out, CD24 (VVSLSLLHLYS) and PRNP (SPPVILLI), established GPI proteins whose PIGA-specific post-omega peptides were recovered here and again in our pan-HLA dataset, direct evidence of genuine binding; both are entering synthetic peptide validation.
Notwithstanding the limitations of a cell line model, the PIGA mutant peptidome differs significantly from that of WT, and these changes in antigen presentation may affect the role of PNH cells both as antigen-presenting cells and as targets of the immune response and may help in immunopeptidomic biomarker development.
DISCLOSURES
Kartik Lakhotiya, MS: No relevant conflicts of interest to declare.